Page last updated: 2024-10-31

nafamostat and Hypercoagulability

nafamostat has been researched along with Hypercoagulability in 2 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Research Excerpts

ExcerptRelevanceReference
"The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms."2.72COVID-19-associated coagulopathy and disseminated intravascular coagulation. ( Asakura, H; Ogawa, H, 2021)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Asakura, H1
Ogawa, H1
Tomita, N1
Kanamori, H1
Fujita, H1
Maruta, A1
Naitoh, A1
Nakamura, S1
Ota, Y1
Nozue, N1
Kihara, M1
Ishigatsubo, Y1

Reviews

1 review available for nafamostat and Hypercoagulability

ArticleYear
COVID-19-associated coagulopathy and disseminated intravascular coagulation.
    International journal of hematology, 2021, Volume: 113, Issue:1

    Topics: Adult; Anticoagulants; Benzamidines; Blood Coagulation Disorders; Blood Coagulation Tests; COVID-19;

2021

Other Studies

1 other study available for nafamostat and Hypercoagulability

ArticleYear
Granulomatous tubulointerstitial nephritis induced by all-trans retinoic acid.
    Anti-cancer drugs, 2001, Volume: 12, Issue:8

    Topics: Aged; Benzamidines; Dalteparin; Drug Administration Schedule; Gabexate; Guanidines; Humans; Idarubic

2001